ClinicalTrials.gg
RecruitingNCT05887440ISOWALKUpdated Sep 5, 2023

Isokinetic Strength Training in Hemiparetic Patient With Knee Extension Thrust

An interventional study of isokinetic strength training of knee extensor and flexor muscles in Hemiparesis/Hemiplegia (One Sided Weakness/Paralysis) and Gait Disorder, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Rennes University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Paresis with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Paresis · France.

Planned enrollment
20th of 22
12 · median 40
Started
2023
with 3 others
No phase
22 of 26
9 open now
Primary completion
2026-08
later than 3 of 11 live
Registered
16th of 26
by date
Lead sponsor
2 of 26
Rennes University Hospital

Among the 26 studies in Paresis with a site in France, this one is the 20th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2023, is one of 22 with no phase, reaches primary completion later than 3 of the 11 other live ones, and was the 16th registered.

Paresis

473 studies on the registry are indexed under Paresis; 121 are open to participants now.

Browse Paresis studies →

Open to participants now

12 of the 26 studies in Paresis with a site in France are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 84 Paresis studies recruiting now, 34 (40%) set no upper age limit and 27 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Paresis with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to assess the impact of an isokinetic strength training of knee flexor and extensor muscles on walking performance in hemiparetic patients with knee extension thrust.

Read the detailed description

The study will be interventional single case experimental design (SCED) with multiple baseline design. SCED are experimental designs aiming at testing the effect of an intervention using a small number of patients using repeated measurements, sequential and randomized introduction of an intervention and method-specific data analysis, including visual analysis and specific statistics.

During baseline, patients will have a rehabilitation program in day hospital (4 days per week) with physiotherapy and physical activity and if necessary occupational and speech therapy. Isokinetic strength training will be added to this conventionnal rehabilitation program and will begin after 3, 4 or 5 weeks of baseline according to randomization

12 patients will be included in this study (6 patients in subacute stage and 6 in chronic stage ).

03

Conditions studied

  • Hemiparesis/Hemiplegia (One Sided Weakness/Paralysis)
  • Gait Disorder

Keywords

  • Stroke
  • Extensor thrust
  • resistance training
  • Isokinetic
  • walking speed
  • rehabilitation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hemiparetic patient (hemorragic or ischemic stroke)
  • Subacute stage (\< 6 Months) ou chronic stage of stroke (> 6 months) (6 patients in each group)
  • Age between 18 and 75 years
  • Able to walk 10 meters independently without any assistive devices
  • Knee extension thrust during stance phase of gait cycle (rapid posterior movement of the knee toward extension)
  • Scheduled rehabilitation program with isokinetic strength training
  • affiliation to a social security
  • Patients who received and signed

Exclusion criteria

Exclusion Criteria:

  • Major comprehension deficit that not allow to give and participate to isokinetic strength training (assessed with comprehension subscore of Langague screening Test)
  • non stable (unstable cardiovascular condition)
  • musculoskeletal disorders with knee pain that not allowed isokinetic strength training
  • Botulinum toxin injection less than 3 months or repeated injection in lower limb,
  • Proprioception trouble assessed with proprioception section of the Fugl-Meyer Assessment [FMA-P] 0/2
  • spasticity of triceps surae ≥2 (Modified Ashworth scale)
  • ankle dorsiflexion angle less than 90°
  • pregnant women or breastfeeding
  • persons with safety measure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Outcomes assessor)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    3 assessments

    The randomisation provides for 3 assessments of baseline

    Behavioral: isokinetic strength training of knee extensor and flexor muscles

  • Experimental
    4 assessments

    The randomisation provides for 4 assessments of baseline

    Behavioral: isokinetic strength training of knee extensor and flexor muscles

  • Experimental
    5 assessments

    The randomisation provides for 5 assessments of baseline

    Behavioral: isokinetic strength training of knee extensor and flexor muscles

Interventions

  • Behavioralisokinetic strength training of knee extensor and flexor muscles

    Patients underwent an isokinetic strength training program with 3 sessions per week during five weeks. Program consists of excentric contraction of knee flexor and extensor muscles (4 x 7 Contractions at 30°/s) and concentric contractions at maximal speed where patients can perform 40% of his maximal isometric torque for knee flexor and extensor muscles (2x10 for knee flexors and 2x10 for knee extensors)

06

What researchers measure

Primary outcomes

  1. spontaneous walking speed

    Spontaneous walking speed of hemiparetic patients recorded with 3D gait analysis

    Time frame: 25 weeks

Secondary outcomes

  1. Extensor thrust analysis

    Extensor thrust at spontaneous and maximal walking speed and during dual task recorded with 3D gait analysis

    Time frame: 25 weeks

  2. Walking speed

    assessment of walking speed in two conditions (maximal speed and dual task)

    Time frame: 25 weeks

  3. Stairs test

    time to ascend and descend stairs (maximal speed)

    Time frame: 25 weeks

  4. Inclined plan

    time to walk in an inclined plan (maximal speed)

    Time frame: 25 weeks

  5. 6-minute walk test

    Assessment of maximum gait perimeter during a 6MWT (6-minute walk test :6MWT)

    Time frame: 25 weeks

  6. Sit to stand test

    1 minute sit to stand test (number of repetitions)

    Time frame: 25 weeks

  7. Extensor thrust during locomotor tasks

    Extensor thrust analysis with inertial measurement unit (stairs, inclined walk, 6MWT and sit to stand )

    Time frame: 25 weeks

  8. Fatigue

    Fatigue severity scale : FSS (minimum 9 -maximum 63 ; a higher score means higher level of fatigue)

    Time frame: 25 weeks

  9. Likert Scale

    self perception of walking stability, fear of fall, trouble with extensor thrust with a likert scale

    Time frame: 25 weeks

  10. Strength

    strength of knee flexor and extensor muscles assessed with isokinetic dynamometer

    Time frame: 25 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Aug 2026, 35 months after the start.

Of 223 non-industry interventional studies with no phase under Paresis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 55. This study's planned 35 months is close to that.

Counting every sponsor, half of 241 studies reached it within 32 months; a quarter within 13 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2023
First posted
Jun 2, 2023
StartActual
Aug 21, 2023
Primary completionEst.
Aug 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05887440
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Aug 21, 2023
Primary completion
Aug 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Sep 5, 2023

Study contacts

Sophie HAMEAU, PhD
Contact
sophie.hameau@chu-rennes.fr
299284218 ext. +33
Krsitell COAT
Contact
kristell.coat@chu-rennes.fr
0299282555
Sophie HAMEAU, PhD
principal investigator · Rennes University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion